image credit: Adobe Stock

FDA approves bispecific drug from Pfizer for multiple myeloma

August 14, 2023

As with other types of cancers, researchers have sought ways to turn the immune system against multiple myeloma. Their efforts have borne fruit with engineered T cell therapies like Bristol Myers Squibb and 2Seventy Bio’s Abecma and J&J and Legend Biotech’s Carvykti.

Those so-called CAR-T drugs are made from patients’ own T cells and require a complex manufacturing process, although for some patients treatment can deliver lasting benefits with a single infusion.

Elrexfio, Tecvayli and Talvey are off-the-shelf drugs called “bispecific” antibodies, binding to proteins on both diseased cells and T cells to trigger an immune response. They are given for as long as patients can tolerate and their disease remains in check.

Read More on Biopharma Dive